Search

Search Constraints

You searched for: Author/Creator Nusch, Arnd

Search Results

1. Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3, 717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). (February 2021)

2. Corrigendum to "Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3, 717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)" [Lung Cancer 152 (2021) 174–184]. (July 2021)

3. Erratum to "First-line ribociclib plus letrozole for postmenopausal women with HR+, HER2- ABC: MONALEESA-2 safety results" [Breast 36 (Suppl. 1) (November 2017) S44–S45]. (August 2018)

4. First-Line Ribociclib Plus Letrozole for Postmenopausal Women with HR+, HER2-ABC: Manaleesa-2 Safety Results. (November 2017)

5. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Issue 9 (September 2017)

6. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Issue 9 (September 2017)

8. Overall Survival and Patient-Reported Impairment by Fatigue, Pain and Treatment Time in Patients with Advanced Breast Cancer in Routine Practice: Results from the Prospective German TMK Cohort Study. (November 2017)

9. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. (September 2017)

10. Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study. (December 2020)